Yong-Wan Kim

Dr. Yong-Wan Kim

Bio Pharm Dongsung (South Korea), Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TKTara Man Kadayat
Tara Man Kadayat
SBSuhrid Banskota
Suhrid Banskota
PGPallavi Gurung
Pallavi Gurung
GBGanesh Bist
Ganesh Bist
TMTil Bahadur Thapa Magar
Til Bahadur Thapa Magar
ELEung-Seok Lee
Eung-Seok Lee

1 March 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SJSHIVAKUMAR JALDE
SHIVAKUMAR JALDE
Anil Kumar ChauhanAnil Kumar Chauhan
Anil Kumar Chauhan
JLJi Hoon Lee
Ji Hoon Lee
PCPankaj Kumar Chaturvedi
Pankaj Kumar Chaturvedi
JPJoon-Suk Park
Joon-Suk Park
YKYong-Wan Kim
Yong-Wan Kim

30 April 2004 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
WAWoong Shick Ahn
Woong Shick Ahn
SBSu Mi Bae
Su Mi Bae
JLJoon Mo Lee
Joon Mo Lee
SNSung Eun Namkoong
Sung Eun Namkoong
SHSei-Jun Han
Sei-Jun Han
YKYong-Wan Kim
Yong-Wan Kim

1 February 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SPSeojeong Park
Seojeong Park
TMTil Bahadur Thapa Magar
Til Bahadur Thapa Magar
TKTara Man Kadayat
Tara Man Kadayat
HLHwa Jong Lee
Hwa Jong Lee
GBGanesh Bist
Ganesh Bist
YKYoungjoo Kwon
Youngjoo Kwon

1 January 2015 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TKTara Man Kadayat
Tara Man Kadayat
CPChanmi Park
Chanmi Park
KJKyu-Yeon Jun
Kyu-Yeon Jun
TMTil Bahadur Thapa Magar
Til Bahadur Thapa Magar
GBGanesh Bist
Ganesh Bist
ELEung-Seok Lee
Eung-Seok Lee

21 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PGPallavi Gurung
Pallavi Gurung
JLJunmo Lim
Junmo Lim
RSRajeev Shrestha
Rajeev Shrestha
YKYong-Wan Kim
Yong-Wan Kim
We hypothesized that photodynamic therapy (PDT) with Chlorin e6 (Ce6) enhances antitumor abscopal effects via inhibition of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) immune checkpoint. By using syngeneic melanoma and pancreatic tumor mouse models, we studied the Ce6-PDT-induced immune responses in local and distant tumor microenvironments. In addition, the Ce6-PDT's target in the PD-1/PD-L1 interaction was analyzed in MC38-hPD-L1 colon cancer and PD-1 expressing Jurkat T cell coculture. The tumors in the irradiated and non-irradiated sites in the abscopal effective (Abseff) group of both mouse models were regressed, proving the abscopal effect. The immunogenic effect in the Abseff group was associated with an expansion of T cell and other immune cells infiltration without changes in the CD39+ population in either the right or left tumors compared to control group. Furthermore, the abscopal ineffective (Absineff) group demonstrated lesser increase of T cells, decreased immune cell infiltration, and increased CD39-expressing Treg cells without suppression of tumor growth. In the coculture with PD-1-expressing Jurkat T cell, Ce6-PDT efficiently suppressed the PD-1/PD-L1 interactions by increasing the proliferation and cytotoxic activity of CD8+ T cells while decreasing CD39-expressing Treg cells in a dose-dependent manner. Likewise, the inhibition of PD-1/PD-L1 interactions was also correlated with the increased production of IL-2 and Granzyme B. Our findings imply that Ce6-PDT is a promising immunotherapy with the potential to improve the abscopal effect.